PT - JOURNAL ARTICLE AU - Martínez-Sáez, Olga AU - Pascual, Tomás AU - Brasó-Maristany, Fara AU - Chic, Nuria AU - González-Farré, Blanca AU - Sanfeliu, Esther AU - Rodríguez, Adela AU - Martínez, Débora AU - Galván, Patricia AU - Belén Rodríguez, Anna AU - Schettini, Francesco AU - Conte, Benedetta AU - Vidal, Maria AU - Adamo, Barbara AU - Martinez, Antoni AU - Muñoz, Montserrat AU - Moreno, Reinaldo AU - Villagrasa, Patricia AU - Salvador, Fernando AU - Ciruelos, Eva M. AU - Faull, Iris AU - Odegaard, Justin I. AU - Prat, Aleix TI - Circulating tumor DNA dynamics using a standardized multi-gene panel in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy AID - 10.1101/2020.06.29.20142257 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.29.20142257 4099 - http://medrxiv.org/content/early/2020/06/29/2020.06.29.20142257.short 4100 - http://medrxiv.org/content/early/2020/06/29/2020.06.29.20142257.full AB - Circulating tumor DNA (ctDNA) levels may predict response to anticancer drugs1, including CDK4/6 inhibitors and endocrine therapy combinations (CDK4/6i+ET)2; however, critical questions remain unanswered such as which assay or statistical method to use3. Here, we obtained paired plasma samples at baseline and week 4 in 45 consecutive patients with advanced breast cancer treated with CDK4/6i+ET. ctDNA was detected in 96% of cases using the 74-gene Guardant360 assay4,5. A variant allele fraction ratio (VAFR) was calculated for each of the 79 detected mutations between both time-points. Mean of all VAFRs (mVAFR) was computed for each patient. In our dataset, mVAFR was significantly associated with progression-free survival (PFS). Baseline VAF, on-treatment VAF or absolute changes in VAF were not associated with PFS. These findings demonstrate that ctDNA dynamics using a standardized multi-gene panel and a unique methodological approach predicts treatment outcome. Clinical trials in patients with an unfavorable ctDNA response are needed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was designed by investigators from Hospital Clinic. Funding sources had no role in the design and conduction of this study, and in the analysis and interpretation of data. Guardant Health provided the assay. This study was funded by Instituto de Salud Carlos III (to A.P.), Breast Cancer Research Foundation (to A.P.), PhD4MD (to N.C.), Fundaci&oacute La Marat&oacute TV3 (to A.P), RESCUER Horizon 2020 (to A.P.), Save the Mama (to A.P.), Pas a Pas (to A.P.), Asociaci&oacuten C&aacutencer de Mama Metast&aacutesico (to A.P.), Fundaci&oacuten Cient&iacutefica Asociaci&oacuten Espa&ntildeola Contra el C&aacutencer (to F.B.M.) and Fundaci&oacuten SEOM (SEOM 2018 Grant: Fellowship for Training in Research in Reference Centers to T.P.). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee of the Hospital Clinic approved the studyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.